He will serve as head of the compensation committee.
Barberich founded Sepracor Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, and served as chairman and chief executive officer for over 20 years.
Under his leadership, Sepracor commercialized and partnered several products, including Allegra, Brovana, Clarinex, Lunesta and Xopenex. Before founding Sepracor, Barberich was a senior executive at Millipore Corp.
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialisation of therapies for glaucoma and other eye diseases.
The company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development.
Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism.
Additionally, the company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
GSK's meningitis vaccine candidate accepted for FDA review
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
AbbVie announces interim evaluation of Atogepant Phase three, open-label 156-week extension study